Clinical Research Support Center, Tomishiro Central Hospital, Okinawa,
Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
Nephron. 2018;140(4):240-248. doi: 10.1159/000493470. Epub 2018 Oct 19.
Abnormal chronic kidney disease-mineral and bone disorder (CKD-MBD) markers have been associated with adverse outcomes in hemodialysis (HD) patients. Dialysate calcium concentration (D-Ca) likely influences serum calcium and phosphorus levels. Optimal D-Ca level remains unclear. We hypothesized that higher D-Ca is associated with cardiovascular events and mortality among Japanese HD patients.
Enrollment data of chronic HD patients in the prospective observational study JDOPPS, phases 1-5 (1999-2015), provided exposures and covariates. All-cause mortality, non-arrhythmic cardiovascular events (NonAR-CVE), or their composites were analyzed by D-Ca, and divided into 2.5, 2.75, and 3.0 mEq/L. To minimize confounding by indication, analyses were restricted to facilities in which at least 90% of patients received the same D-Ca prescription. Association of D-Ca level with outcomes was evaluated in Cox models stratified by phase and accounting for facility clustering. Covariates describing patient demographics, comorbidities, laboratory values, CKD-MBD therapy, and facility attributes provided adjustment.
Of 9,201 patients included, 25.0% had D-Ca of 2.5 mEq/L; 6.8% D-Ca 2.75; and 68.2% D-Ca 3.0. Median follow-up time was 2.03 years. D-Ca was not associated with all-cause mortality, with hazards ratios for 2.5 vs. 3.0 mEq/L of 0.90 and 95% CI (0.73-1.11), nor with other outcomes. One effect modification occurred, protective for lower D-Ca on NonAR-CVE in the absence of cardiovascular comorbidities (p = 0.032), although corresponding D-Ca effects were not significant after multiple comparisons adjustment (p = 0.261 [D-Ca 2.5] and 0.125 [D-Ca 2.75]).
Lowering D-Ca level below 3.0 mEq/L seems not to have a meaningful effect on patient outcomes.
异常的慢性肾脏病-矿物质和骨异常(CKD-MBD)标志物与血液透析(HD)患者的不良结局相关。透析液钙浓度(D-Ca)可能影响血清钙和磷水平。最佳 D-Ca 水平仍不清楚。我们假设较高的 D-Ca 与日本 HD 患者的心血管事件和死亡率相关。
前瞻性观察研究 JDOPPS 的阶段 1-5(1999-2015 年)的慢性 HD 患者的入组数据提供了暴露和协变量。全因死亡率、非心律失常性心血管事件(NonAR-CVE)或其组合通过 D-Ca 进行分析,并分为 2.5、2.75 和 3.0 mEq/L。为了最大限度地减少指示性混杂,分析仅限于至少 90%的患者接受相同 D-Ca 处方的设施。在按阶段分层并考虑设施聚类的 Cox 模型中评估 D-Ca 水平与结局的关联,并对患者人口统计学、合并症、实验室值、CKD-MBD 治疗和设施特征进行了调整。
在纳入的 9201 名患者中,25.0%的患者 D-Ca 为 2.5 mEq/L;6.8%为 D-Ca 2.75;68.2%为 D-Ca 3.0。中位随访时间为 2.03 年。D-Ca 与全因死亡率无关,2.5 与 3.0 mEq/L 的危险比为 0.90 和 95%CI(0.73-1.11),与其他结局也无关。发生了一种效应修饰,在没有心血管合并症的情况下,较低的 D-Ca 对 NonAR-CVE 具有保护作用(p=0.032),尽管在多次比较调整后,相应的 D-Ca 效应并不显著(p=0.261[D-Ca 2.5]和 0.125[D-Ca 2.75])。
将 D-Ca 水平降低到 3.0 mEq/L 以下似乎对患者的结局没有明显的影响。